Nathan AS - Search Results

1

Association Between Diagnosis-to-Limb Revascularization Time and Clinical Outcomes in Outpatients With Chronic Limb-Threatening Ischemia: Insights From the CLIPPER Cohort.

Fanaroff AC, Dayoub EJ, Yang L, Schultz K, Ramadan OI, Wang GJ, Damrauer SM, Genovese EA, Secemsky EA, Parikh SA, Nathan AS, Kohi MP, Weinberg MD, Jaff MR, Groeneveld PW, Giri JS. Fanaroff AC, et al. Among authors: nathan as. J Am Heart Assoc. 2024 May 7;13(9):e033898. doi: 10.1161/JAHA.123.033898. Epub 2024 Apr 19. J Am Heart Assoc. 2024. PMID: 38639376 Free article.

2

Bioresorbable Scaffolds for Coronary Artery Disease.

Nathan A, Kobayashi T, Kolansky DM, Wilensky RL, Giri J. Nathan A, et al. Curr Cardiol Rep. 2017 Jan;19(1):5. doi: 10.1007/s11886-017-0812-7. Curr Cardiol Rep. 2017. PMID: 28108898 Review.

3

How Should We Address Carotid Artery Stenosis Around the Time of Open-Heart Surgery?

Giri J, Nathan A. Giri J, et al. JACC Cardiovasc Interv. 2017 Feb 13;10(3):299-301. doi: 10.1016/j.jcin.2016.12.018. JACC Cardiovasc Interv. 2017. PMID: 28183470 Free article. No abstract available.

4

Nitinol Self-Expanding Stents for the Superficial Femoral Artery.

Nathan A, Kobayashi T, Giri J. Nathan A, et al. Interv Cardiol Clin. 2017 Apr;6(2):227-233. doi: 10.1016/j.iccl.2016.12.006. Epub 2017 Jan 5. Interv Cardiol Clin. 2017. PMID: 28257770 Review.

5

Too Hot? Too Cold? When Is it "Just Right" to Stop Dual Antiplatelet Therapy After PCI With DES?

Giri J, Nathan A. Giri J, et al. JACC Cardiovasc Interv. 2017 Aug 28;10(16):1631-1632. doi: 10.1016/j.jcin.2017.07.004. JACC Cardiovasc Interv. 2017. PMID: 28838472 Free article. No abstract available.

6

Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications.

Goli RR, Contractor MM, Nathan A, Tuteja S, Kobayashi T, Giri J. Goli RR, et al. Curr Atheroscler Rep. 2017 Nov 4;19(12):56. doi: 10.1007/s11883-017-0698-2. Curr Atheroscler Rep. 2017. PMID: 29103068 Review.

7

Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes.

Mangels DR, Nathan A, Tuteja S, Giri J, Kobayashi T. Mangels DR, et al. Curr Treat Options Cardiovasc Med. 2018 Feb 27;20(2):17. doi: 10.1007/s11936-018-0603-5. Curr Treat Options Cardiovasc Med. 2018. PMID: 29488032 Review.

8

Is it Time to Abandon Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation on Anticoagulation?

Giri J, Nathan A. Giri J, et al. JACC Cardiovasc Interv. 2018 Apr 9;11(7):635-637. doi: 10.1016/j.jcin.2017.12.002. Epub 2018 Mar 14. JACC Cardiovasc Interv. 2018. PMID: 29550087 Free article. No abstract available.

9

Prasugrel or Ticagrelor for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Does it Matter?

Giri J, Nathan A. Giri J, et al. JACC Cardiovasc Interv. 2018 Aug 27;11(16):1587-1589. doi: 10.1016/j.jcin.2018.04.047. Epub 2018 May 24. JACC Cardiovasc Interv. 2018. PMID: 29805110 Free article. No abstract available.

10

Association Between 30-Day Mortality After Percutaneous Coronary Intervention and Education and Certification Variables for New York State Interventional Cardiologists.

Khatana SAM, Fiorilli PN, Nathan AS, Kolansky DM, Mitra N, Groeneveld PW, Giri J. Khatana SAM, et al. Among authors: nathan as. Circ Cardiovasc Interv. 2018 Sep;11(9):e006094. doi: 10.1161/CIRCINTERVENTIONS.117.006094. Circ Cardiovasc Interv. 2018. PMID: 30354589 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

108 results

Search Page